 COPENHAGEN, Denmark, Dec. 15, 2022 GLOBE NEWSWIRE -- Evaxion Biotech AS NASDAQ: EVAX Evaxion or the Company, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies cancer vaccines EVX-01 and EVX-02 in the second quarter of 2023. 